National Research Council Canada

nrc-cnrc.gc.ca

The National Research Council of Canada (NRC) is the Government of Canada's largest research and technology organization. Working with our partners, we're delivering a national platform for innovation. We conduct research, support small and medium-sized companies to help them scale up and compete and we connect Canadian innovators to leading R&D capabilities. We also enable cross-sector partnership and collaboration here at home.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

CENTOGENE LAUNCHES NEW CENTOGENOME®, WORLD’S MOST COMPREHENSIVE WHOLE GENOME SEQUENCING SOLUTION FOR DIAGNOSIS OF RARE AND NEURODEGENERATIVE DISEASES

Globenewswire | April 13, 2023

news image

Centogene N.V. the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options. Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially avai...

Read More

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

news image

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

news image

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More

Cell and Gene Therapy

BIOCYTOGEN ANNOUNCES COLLABORATION WITH FINEIMMUNE TO DEVELOP TCR-MIMIC ANTIBODY-BASED CELL THERAPY

Biocytogen | September 16, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its pro...

Read More
news image

MedTech, Industrial Impact

CENTOGENE LAUNCHES NEW CENTOGENOME®, WORLD’S MOST COMPREHENSIVE WHOLE GENOME SEQUENCING SOLUTION FOR DIAGNOSIS OF RARE AND NEURODEGENERATIVE DISEASES

Globenewswire | April 13, 2023

Centogene N.V. the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options. Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially avai...

Read More
news image

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More
news image

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More
news image

Cell and Gene Therapy

BIOCYTOGEN ANNOUNCES COLLABORATION WITH FINEIMMUNE TO DEVELOP TCR-MIMIC ANTIBODY-BASED CELL THERAPY

Biocytogen | September 16, 2022

Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its pro...

Read More